Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Completed
- Conditions
- Colorectal CancerRefractory Colorectal CancerMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 520
- Registration Number
- NCT06202417
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model
Recruiting
- Conditions
- MetastasisPredictive Cancer Model
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 166
- Registration Number
- NCT06202404
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06196788
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06196671
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Phase 4
Recruiting
- Conditions
- Advanced Thyroid Cancer Patients Who Received Target Therapy
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT06195228
- Locations
- 🇨🇳
Shanxi Cancer Hospital, Shanxi, Taiyuan, China
🇨🇳Caixia Liu, Hohhot, Inner Mongolia, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Phase 3
Recruiting
- Conditions
- Esophageal Squamous Cell CarcinomaOligometastatic DiseaseRadiotherapy
- Interventions
- Combination Product: PD-1 inhibitor+/- chemotherapy combined with local therapyDrug: systemic therapy alone
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 354
- Registration Number
- NCT06190782
- Locations
- 🇨🇳
Fudan University Shanghai cancer center, Shanghai, China
Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy
Phase 1
Recruiting
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- Radiation: thoracic radiotherapy
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 28
- Registration Number
- NCT06187740
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Phase 2
Recruiting
- Conditions
- HER-2 Protein OverexpressionNon-muscle Invasive Bladder Cancer
- Interventions
- Drug: Bacillus Calmette Guerin Vaccine
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06187506
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma
Phase 1
Recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- Combination Product: Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 9
- Registration Number
- NCT06182735
- Locations
- 🇨🇳
Jian Zhang, Shanghai, China
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
Phase 3
Recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 266
- Registration Number
- NCT06177301
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath